Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Jul;62(1):105–108. doi: 10.1038/bjc.1990.238

Full dose chemotherapy in elderly patients with non-Hodgkin's lymphoma: a feasibility study using a mitoxantrone containing regimen.

P Sonneveld 1, J J Michiels 1
PMCID: PMC1971727  PMID: 2390469

Abstract

A prospective study was performed to evaluate the feasibility of full dose chemotherapy given on schedule in elderly patients with unfavourable non-Hodgkin's lymphoma, stage IE, III and IV. Using a combination regimen of six courses of cyclophosphamide, mitoxantrone, vincristine and prednisone (CNOP) given every 4 weeks, no serious toxicity was encountered in a group of 30 consecutive patients with a mean age of 70.4 years. A 60% complete response rate was observed and a total response rate of 90%. The disease-free survival of complete responders was 50% at 1 year. The overall survival was also 50% at 1 year. In 148 courses of CNOP only two serious infectious episodes were noted, i.e. one herpes zoster infection and one case of bronchopneumonia. Asymptomatic transient thrombocytopenia and granulocytopenia were commonly observed. Nadirs of white blood cells were WHO grade 1, 2, 3 and 4 in six, five, twelve and two patients respectively and nadirs of thrombocytopenia were WHO grade 0 and 1 (22 patients) or 2 (three patients). Based on low white blood cell counts, a delay of 1 week before administration of the next course of CNOP was necessary in 7% of the courses. No dose reductions were applied. Toxicity other than transient granulocytopenia was minor and consisted of alopecia and nausea. WHO grade 0-2. CNOP related toxicity was never a reason to stop treatment. It is concluded that CNOP chemotherapy without initial dose reduction in elderly patients with intermediate and high grade malignant non-Hodgkin's lymphoma is feasible and that no major toxicity is observed.

Full text

PDF
105

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson T., Chabner B. A., Young R. C., Berard C. W., Garvin A. J., Simon R. M., DeVita V. T., Jr Malignant lymphoma. 1. The histology and staging of 473 patients at the National Cancer Institute. Cancer. 1982 Dec 15;50(12):2699–2707. doi: 10.1002/1097-0142(19821215)50:12<2699::aid-cncr2820501202>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  2. Armitage J. O., Potter J. F. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age. J Am Geriatr Soc. 1984 Apr;32(4):269–273. doi: 10.1111/j.1532-5415.1984.tb02020.x. [DOI] [PubMed] [Google Scholar]
  3. Armitage J. O., Weisenburger D. D., Hutchins M., Moravec D. F., Dowling M., Sorensen S., Mailliard J., Okerbloom J., Johnson P. S., Howe D. Chemotherapy for diffuse large-cell lymphoma--rapidly responding patients have more durable remissions. J Clin Oncol. 1986 Feb;4(2):160–164. doi: 10.1200/JCO.1986.4.2.160. [DOI] [PubMed] [Google Scholar]
  4. Boyd D. B., Coleman M., Papish S. W., Topilow A., Kopel S. K., Bernhardt B., Files J. C., Schwartz S., Gaynor M., McDermott D. COPBLAM III: infusional combination chemotherapy for diffuse large-cell lymphoma. J Clin Oncol. 1988 Mar;6(3):425–433. doi: 10.1200/JCO.1988.6.3.425. [DOI] [PubMed] [Google Scholar]
  5. Brusamolino E., Bertini M., Guidi S., Vitolo U., Inverardi D., Merante S., Colombo A., Resegotti L., Bernasconi C., Ferrini P. R. CHOP versus CNOP (N = mitoxantrone) in non-Hodgkin's lymphoma: an interim report comparing efficacy and toxicity. Haematologica. 1988 May-Jun;73(3):217–222. [PubMed] [Google Scholar]
  6. Connors J. M. Infusions, age, and drug dosages: learning about large-cell lymphoma. J Clin Oncol. 1988 Mar;6(3):407–408. doi: 10.1200/JCO.1988.6.3.407. [DOI] [PubMed] [Google Scholar]
  7. Dixon D. O., Neilan B., Jones S. E., Lipschitz D. A., Miller T. P., Grozea P. N., Wilson H. E. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol. 1986 Mar;4(3):295–305. doi: 10.1200/JCO.1986.4.3.295. [DOI] [PubMed] [Google Scholar]
  8. Fisher R. I., DeVita V. T., Jr, Hubbard S. M., Longo D. L., Wesley R., Chabner B. A., Young R. C. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. Ann Intern Med. 1983 Mar;98(3):304–309. doi: 10.7326/0003-4819-98-3-304. [DOI] [PubMed] [Google Scholar]
  9. Fisher R. I., Miller T. P., Dana B. W., Jones S. E., Dahlberg S., Coltman C. A., Jr Southwest oncology group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas. Semin Hematol. 1987 Apr;24(2 Suppl 1):21–25. [PubMed] [Google Scholar]
  10. Goh K. O., Williams T. F. Non-Hodgkin's lymphoma in elderly patients. J Am Geriatr Soc. 1983 Nov;31(11):704–709. doi: 10.1111/j.1532-5415.1983.tb04158.x. [DOI] [PubMed] [Google Scholar]
  11. Klimo P., Connors J. M. Updated clinical experience with MACOP-B. Semin Hematol. 1987 Apr;24(2 Suppl 1):26–34. [PubMed] [Google Scholar]
  12. Laurence J., Coleman M., Allen S. L., Silver R. T., Pasmantier M. Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen. Ann Intern Med. 1982 Aug;97(2):190–195. doi: 10.7326/0003-4819-97-2-190. [DOI] [PubMed] [Google Scholar]
  13. Mead G. M., Macbeth F. R., Williams C. J., Ryall R. D., Wright D. H., Whitehouse J. M. Poor prognosis non-Hodgkin's lymphoma in the elderly: clinical presentation and management. Q J Med. 1984 Summer;53(211):381–390. [PubMed] [Google Scholar]
  14. O'Connell M. J., Earle J. D., Harrington D. P., Johnson G. J., Glick J. H. Initial chemotherapy doses for elderly patients with malignant lymphoma. J Clin Oncol. 1986 Sep;4(9):1418–1418. [PubMed] [Google Scholar]
  15. Skarin A. T., Canellos G. P., Rosenthal D. S., Case D. C., Jr, MacIntyre J. M., Pinkus G. S., Moloney W. C., Frei E., 3rd Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol. 1983 Feb;1(2):91–98. doi: 10.1200/JCO.1983.1.2.91. [DOI] [PubMed] [Google Scholar]
  16. Solal-Celigny P., Chastang C., Herrera A., Desaint B., Renoux M., Gaulard P., Bernard J. F., Brousse N., Boivin P. Age as the main prognostic factor in adult aggressive non-Hodgkin's lymphoma. Am J Med. 1987 Dec;83(6):1075–1079. doi: 10.1016/0002-9343(87)90944-2. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES